At the heart of Elixia’s pioneering efforts in cardiology and nephrology is our unique and multidisciplinary Cardio-Renal Network. We are ranked among the top 1% globally for clinical trial enrollment in cardio-renal research, with an exceptional national footprint dedicated to cardiology and/or nephrology encompassing 350+ studies to date.

Deep Expertise in Cardio-Renal Overlap

At Elixia, we pride ourselves on understanding of the intricate interplay between renal diseases and complex cardiovascular conditions. This comprehensive insight is the result of close collaborations with some of the largest nephrology networks in the United States. Our network includes more than 1,500 nephrologists across 16 states, culminating in the largest one-of-a-kind cardio-renal clinical trials network in the U.S., spread across four crucial geographical regions.

Elixia’s success is owed not only to our vast network but also our strategic partnerships with pharma giants like AstraZeneca, Bayer, Cara Therapeutics, GlaxoSmithKline and Tricida. These alliances empower Elixia to conduct studies in various therapeutic subcategories within cardiology and nephrology, including anemia, chronic kidney disease, chronic renal failure, end-stage renal disease, hyperparathyroidism, metabolic acidosis, overactive bladder, pruritus, and type 2 diabetes.

Leadership and Vision

The driving force behind Elixia’s extraordinary growth is our CEO, Neal Patel, a healthcare and biotechnology entrepreneur with a profound passion for improving accessibility, particularly in underserved communities. His journey began with the establishment of a private R&D laboratory responsible for developing cost-effective diagnostic tests for cardiovascular indications. Over time, Patel developed one of the largest dedicated cardiology networks on the east coast, culminating in the development of the groundbreaking Cardio-Renal Network.

Under his guidance, Elixia’s Cardio-Renal Network has become the largest dedicated clinical trials footprint in the Southeast and the fastest-growing within the cardio-renal specialty in North America. Patel’s strategic foresight has led to Elixia’s meteoric rise, as the company’s total enterprise value has more than quadrupled, our workforce has tripled, and we have garnered numerous accolades for our work in various therapeutic areas.

Pioneering Clinical Trial Solutions

Elixia has always been at the forefront of delivering innovative clinical trial management solutions. Our integrated and technology-forward approach has introduced a new suite of capabilities to enhance the efficiency of clinical trials.

The Elixia Cardio-Renal Network is a testament to the power of innovation, dedication, and strategic collaboration in the field of clinical trials. As we continue to expand our reach and expertise in cardiology and nephrology, Elixia is poised to make a significant impact on the treatment and understanding of complex cardiovascular and renal diseases.